[go: up one dir, main page]

Prohic et al., 2008 - Google Patents

New Treatments for Psoriasis: Biologic Agents

Prohic et al., 2008

View PDF
Document ID
7610727138307900894
Author
Prohic A
Simic D
Kasumagic-Halilovic E
Publication year
Publication venue
Instructions for the authors of the journal “Materia Socio Medica”

External Links

Snippet

Psoriasis is a chronic inflammatory immune skin disease that has a multifactorial genesis. The recognition of psoriasis as a T-cell mediated disease has enabled new treatments that selectively target a specific portion of the immune system. This therapeutic approach is in …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Christensen et al. K/BxN serum-transfer arthritis as a model for human inflammatory arthritis
US20230074746A1 (en) Combined preparations for the treatment of cancer or infection
Hohlfeld Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives.
Feldmann et al. Role of cytokines in rheumatoid arthritis
Weinberg An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis
Gottlieb et al. Recombinantly engineered human proteins: transforming the treatment of psoriasis
Raychaudhuri et al. Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases
Gisondi et al. Targeting tumor necrosis factor-α in the therapy of psoriasis
Ghilardi et al. 30 Years of biotherapeutics development—what have we learned?
EP1034001B1 (en) Cd154 blockade therapy for therapeutic protein inhibitor syndrome
Saini et al. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus
WO1999000143A1 (en) Cd154 blockade therapy for autoimmune diseases
CA2319698A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
Pucino Jr et al. Use of biologics in rheumatoid arthritis: where are we going?
Prohic et al. New Treatments for Psoriasis: Biologic Agents
Gottlieb Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances
Godic New approaches to psoriasis treatment. A review
Kenneth B et al. Evolution of biologic therapies for the treatment of psoriasis
Prohić et al. Targeting psoriasis with new therapies
Weinberg et al. Evidence-based review of biologic therapy for psoriasis: infliximab, etanercept, adalimumab, efalizumab, and alefacept
IMMUNOBIOLOGICS Immunobiologicals for psoriasis: using targeted immunotherapies as pathogenic probes in psoriasis
Chen et al. Progresses in biological-targeted drug therapy for systemic lupus erythematosus
Vaz et al. PSORIATIC ARTHRITIS: AN UPDATE FOR CLINICIANS.
Wilsmann-Theis et al. Biologicals dramatic advances in the treatment of psoriasis
Bull Biological breakthroughs in the treatment of psoriasis